Residual Microglia Following Short-term PLX5622 Treatment in 5xFAD Mice Exhibit Diminished NLRP3 Inflammasome and mTOR Signaling, and Enhanced Autophagy
Maheedhar KodaliiD, Leelavathi Narayana MadhuiD, Yogish SomayajiiD, Sahithi Attaluri, Charles Huard, Prashanta Kumar PandaiD, Goutham ShankariD, Shama Rao, Bing Shuai, Jenny Jaimes Gonzalez, Chris Oake, Catherine HeringiD, Roshni Sara Babu, Sanya Kotian, Ashok Kumar ShettyiD
Abstract
Chronic neuroinflammation represents a prominent hallmark of Alzheimers disease (AD). While moderately activated microglia are pivotal in clearing amyloid beta (A{beta}), hyperactivated microglia perpetuate neuroinflammation. Prior investigations have indicated that the elimination of [~]80% of microglia through a month-long inhibition of the colony-stimulating factor 1 receptor (CSF1R) during the advanced stage of neuroinflammation in 5xFamilial AD (5xFAD) mice mitigates synapse loss and neurodegeneration without impacting A{beta} levels. Furthermore, prolonged CSF1R inhibition diminished the development of parenchymal plaques. Nonetheless, the immediate effects of short-term CSF1R inhibition during the early stages of neuroinflammation on residual microglial phenotype or metabolic fitness are unknown. Therefore, we investigated the effects of 10-day CSF1R inhibition in three-month-old female 5xFAD mice, a stage characterized by the onset of neuroinflammation and minimal A{beta} plaques. We observed [~]65% microglia depletion in the hippocampus and cerebral cortex. The leftover microglia demonstrated a noninflammatory phenotype, with highly branched and ramified processes and reduced NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome complexes. Moreover, plaque-associated microglia were reduced in number with diminished Clec7a (dectin-1) expression. Additionally, both microglia and neurons displayed reduced mechanistic target of rapamycin (mTOR) signaling and autophagy. Biochemical assays validated the inhibition of NLRP3 inflammasome activation, decreased mTOR signaling, and enhanced autophagy. However, short-term CSF1R inhibition did not influence A{beta} plaques, soluble A{beta}-42 levels, or hippocampal neurogenesis. Thus, short-term CSF1R inhibition during the early stages of neuroinflammation in 5xFAD mice promotes the retention of homeostatic microglia with diminished inflammasome activation and mTOR signaling, alongside increased autophagy.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 17
- FWCI
- 2.65
- Field percentile
- top 9%
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A multimodal approach of microglial CSF1R inhibition and GENUS provides therapeutic effects in Alzheimers disease mice
Chinnakkaruppan Adaikkan, Rezaul Islam, … Li‐Huei Tsai·bioRxiv·Apr 27, 2025
- C5aR1 antagonism suppresses inflammatory glial gene expression and alters cellular signaling in an aggressive Alzheimer's model
Nicole D. Schartz, Heidi Yahan Liang, … Andrea J. Tenner·bioRxiv·Aug 22, 2023
- Inhibition of IL34 unveils tissue-selectivity and is sufficient to reduce microglial proliferation in chronic neurodegeneration
Juliane Obst, Emilie Simon, … Diego Gómez‐Nicola·Frontiers in ImmunologyPeer-reviewed·Oct 8, 2020
- Microglial depletion with CSF1R inhibitor during chronic phase of experimental traumatic brain injury reduces neurodegeneration and neurological deficits
Rebecca J. Henry, Rodney M. Ritzel, … David J. Loane·Journal of NeurosciencePeer-reviewed·Feb 24, 2020
- Modulation of mitochondria-ER contacts decrease inflammasome formation and restores amyloid β-peptide phagocytosis in adult mouse microglia
Ming Ho Choi, Luana Naia, Maria Ankarcrona·bioRxiv·Mar 12, 2026
- Noradrenergic signaling controls Alzheimer's disease pathology via activation of microglial β2 adrenergic receptors
Linh Le, Alexis M. Feidler, … Ania Katarzyna Majewska·bioRxiv·Dec 1, 2023